Stockreport

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia [Yahoo! Finance]

Alto Neuroscience, Inc.  (ANRO) 
PDF – Designation highlights the significant unmet need for new treatments for cognitive impairment associated with schizophrenia (CIAS) – – Enrollment remains ongoing in [Read more]